Tarsus Pharmaceuticals, Inc.

Good afternoon and welcome to TARCIS third quarter 2024 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, head of investor relations, to lead off the call. David, you may begin.

Thank you. Before we begin, I encourage everyone to go to the investor section of the TARCIS website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Motawala, our Chief Commercial Officer, Sesha Nirvanan, our Chief Operating Officer, Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer, and joining us for the first time, Dr. Elizabeth Yu, our newly appointed Chief Medical Officer for the Q&A portion. I'd like to draw your attention to slide three, which contains our forward-looking statements During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I will turn the call over to Bobby.

Good afternoon, everyone, and thank you for joining us. 2024 continues to be a year of tremendous growth for TARCIS. as we execute on our vision to revolutionize treatments for patients in need. And I am pleased to share the results of our most successful quarter to date. In the fourth full quarter of our launch, we generated more than $48 million in Xtembe net product sales, driven by more than 41,000 bottles delivered to patients impacted by demonex blepharitis, or DB. As the launch continues to accelerate, we are even more confident in the potential of Xtembe. This confidence stems from continuing to deliver on our strategy and adhering to our category-creating fundamentals. We are executing on all fronts with a sharp focus on education, ease of access, and even more evidence generation to come. We expanded our sales force from approximately 100 to 150 at the end of the third quarter, and we are starting to see a meaningful increase in the number of eye care professionals, or ECPs, prescribing Istanbul. as well as the number of ECPs who write multiple times a week, a leading indicator that depth of prescribing is trending in the right direction. One of my passions as CEO is remaining connected to the field and engaging with ECPs in their clinics. In my most recent field visit, I met with one of our top prescribers and saw firsthand the power of repeat interactions in further deepening the use of Xtemvi and DB patients. These repeat visits, combined with ease of access and shared evidence, are accelerating that prescriber's desire to look for and treat DB in all of their patients. This also illustrates that even our top prescribers haven't come close to reaching their limit. While our sales force is doing great work to further build upon the solid foundation we have established, we are also generating additional evidence to further educate physicians and patients on the impact of DB and potential benefits of Xtemvi. Just last week, groundbreaking positive data in DB patients with myeloma gland disease, or MGD, was presented at the American Academy of Optometry. These data represent the first time a DB therapeutic has demonstrated statistically significant and clinically meaningful improvements in objective measures of MGD and in specific disease symptoms that impact how patients look, feel, and ultimately, seed. Based on conversations with KOLs in the field and at the academy, this data set provides the evidence they have been waiting for as they look to expand their use of Xtembe. In addition to expanding our sales force and generating additional data, we also activated our first direct-to-consumer campaign on streaming television that leverages creative and memorable visuals to illustrate the damaging impact of the disease. The goal of the campaign, which you can view on Xtemvi.com, is to support patients in their journey and understanding of DB and to encourage them to consult with an ECP to see if Xtemvi is right for them. If you haven't seen it, I encourage you to do so, as it is truly a unique and motivating approach to patient education. Finally, we made tremendous progress with payers again this quarter. We secured both additional commercial coverage and the two remaining large Medicare contracts, bringing total covered lives to more than 80%, a remarkable statistic this early in the launch. Turning to our world-class leadership team, you may have noted that we added two very well-established, well-regarded clinical leaders who will further strengthen our position in eye care. It gives me great pleasure to welcome Dr. Elizabeth Yu as our new Chief Medical Officer. Liz has supported us for many years as both our chief medical advisor and a member of our board of directors. And we are pleased to apply her strategic expertise and leadership so directly to our efforts to improve patients' lives. Liz is a distinguished ophthalmologist with more than two decades of real-world experience, and she will no doubt have a significant impact on our newly created medical organization, leading evidence generation, medical education, and providing oversight of patient safety. We are also delighted to welcome Dr. Kate Goodrich to our board of directors. As the chief medical officer of Humana and former chief medical officer of the Centers for Medicare and Medicaid Services, Kate brings a unique skill set and perspective to the board that will help us think more creatively and broadly about ease of access, health equity, and other value-based initiatives to ensure better patient outcomes. Finally, you'll hear from Sesha about our robust pipeline of other category-creating assets that continues to advance. Our accomplishments so far this year, our strength in leadership, and the strategic investments we are making continue to move us closer to achieving our vision of becoming an iCare leader. With that, I will turn the call over to our Chief Commercial Officer, Aziz Matawala, for more details on our commercial progress. Aziz, over to you.